Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegavivint in Advanced Hepatocellular Carcinoma
NCT05797805Phase 2Recruiting
- Sponsor
- Iterion Therapeutics
- Start
- Sep 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tegavivint in hepatocellular carcinoma (HCC), sponsored by Iterion Therapeutics. Started Sep 2023; status: recruiting.
02
Drugs
tegavivint
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05797805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797805.